CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 420 · Search date 2026-07-17 · Methodology v0.6

Aster spathulifolius extract,
does it really help with Reduced body fat?

30-Second Summary
C
Evidence Grade C · 52 · Safety unknown
The 700 mg specification has one short-term trial, without independent replication or durable-loss evidence
What the
research shows
Aster spathulifolius extract at 700 mg/day produced about 3.3 kg of weight loss and about 2.3 kg of fat loss in a 12-week RCT of 44 adults with obesity. Only 41 completed this single company-supported trial, and no independent replication was identified, supporting C with 52 points.
What the
ads claim
Marketing turns a Jeju coastal native plant, concentrated chlorogenic acid, and slogans about targeting body fat into certainty of actual weight loss. Individual recognition means that a study and specification exist; it does not establish effects from every Aster tea or powder or durable obesity treatment.
*

Useful facts when choosing a product

  • The first Korean individual recognition was 2020-11; 2022-36 is a duplicate recognition. The recognized intake is 700 mg/day.
  • The ingredient is an extract of Aster spathulifolius leaves, with a marker specification of 14.4 mg/g chlorogenic acid.
  • It is sold in Korean combination health-functional products including Slimway Diet that provide 700 mg/day.
  • No related adverse events were reported over 12 weeks, but long-term safety evidence is limited. Caution is advised for infants, children, pregnancy, lactation, and allergic conditions.
Gap Measurement · Verdict 420 · C 52
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Cho 2016 RCT assigned 44 adults with BMI from 25 to 30 to Aster spathulifolius extract at 700 mg/day or placebo, and 41 completed the trial. Mean weight fell 3.30 kg, bioimpedance fat mass 2.38 kg, and DXA fat mass 2.26 kg in the extract group, differing from placebo. Lipids, fasting glucose, and HbA1c did not differ between groups, and no product-related adverse events were reported. This first clinical study was supported by Newtree, and no independent replication was identified.

02

Why this is classified as C (52)

One RCT consistently found positive weight and fat-mass outcomes by bioimpedance and DXA, but it was a 44-person, 12-week, company-supported first trial without independent replication, supporting C with 52 points.

Counterpoint. A published short-term weight and fat-loss signal exists for the matching 700 mg/day specification. This does not establish durable loss, improvement in obesity complications, or effects from ordinary Aster products.

Rejudgment record. New verdict — Positive weight and bioimpedance and DXA fat-mass outcomes in one 44-person, 12-week company-supported RCT, but no independent replication and null lipid and glucose markers

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Cho IJ et al. 2016Randomized double-blind placebo-controlled trial41Newtree support and partial government industrial-technology fundingWeight, BMI, fat mass by bioimpedance, DXA and CT, and metabolic markersWeight fell 3.30 kg, bioimpedance fat mass 2.38 kg, and DXA fat mass 2.26 kg; lipids, fasting glucose, and HbA1c did not differ between groups.Key
MFDS first individually recognized ingredient 2020-11Regulatory ingredient informationNot applicableRecognized function, intake, and specificationRegistered for helping reduce body fat at 700 mg/day with 14.4 mg/g chlorogenic acid.Product information
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-17).

Cho IJ, Choung SY, Hwang YC, Ahn KJ, Chung HY, Jeong IK. Aster spathulifolius Maxim extract reduces body weight and fat mass in obese humans. Nutr Res. 2016;36(7):671-678. PMID: 27333958. DOI: 10.1016/j.nutres.2016.03.001.
checked
Ministry of Food and Drug Safety. Aster spathulifolius leaf extract, duplicate individually recognized ingredient 2022-36. November 22, 2022. No PMID or DOI.
checked
Ministry of Food and Drug Safety. Consumer report for Aster spathulifolius extract, first individually recognized ingredient 2020-11. 2020. No PMID or DOI.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

Aster spathulifolius extract x reduced body fat Evidence Grade C card
[Chamgap] Aster spathulifolius extract x reduced body fat — Evidence Grade C·52. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/aster-spathulifolius-extract-body-fat/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.